Triple-low Alerts Do Not Reduce Mortality: A Real-time Randomized Trial.

Anesthesiology

From the Departments of Outcomes Research (D.I.S., A.T., E.J.M., D.Y., E.F., J.C., A.K.) General Anesthesiology (E.F., J.C., C.V., T.K., A.L.K., M.P., M.R., S.D., K.K., A.K.) Anesthesiology Institute and Department of Quantitative Health Sciences (E.J.M., D.Y.), Cleveland Clinic, Cleveland, Ohio the Department of Anesthesiology, St. Louis University, St. Louis, Missouri (W.H.S.).

Published: January 2019

Background: Triple-low events (mean arterial pressure less than 75 mmHg, Bispectral Index less than 45, and minimum alveolar fraction less than 0.8) are associated with mortality but may not be causal. This study tested the hypothesis that providing triple-low alerts to clinicians reduces 90-day mortality.

Methods: Adults having noncardiac surgery with volatile anesthesia and Bispectral Index monitoring were electronically screened for triple-low events. Patients having triple-low events were randomized in real time, with clinicians either receiving an alert, "consider hemodynamic support," or not. Patients were blinded to treatment. Helpful responses to triple-low events were defined by administration of a vasopressor within 5 min or a 20% reduction in end-tidal volatile anesthetic concentration within 15 min.

Results: Of the qualifying patients, 7,569 of 36,670 (20%) had triple-low events and were randomized. All 7,569 were included in the primary analysis. Ninety-day mortality was 8.3% in the alert group and 7.3% in the nonalert group. The hazard ratio (95% CI) for alert versus nonalert was 1.14 (0.96, 1.35); P = 0.12, crossing a prespecified futility boundary. Clinical responses were helpful in about half the patients in each group, with 51% of alert patients and 47% of nonalert patients receiving vasopressors or having anesthetics lowered after start of triple low (P < 0.001). There was no relationship between the response to triple-low events and adjusted 90-day mortality.

Conclusions: Real-time alerts to triple-low events did not lead to a reduction in 90-day mortality, and there were fewer responses to alerts than expected. However, similar mortality with and without responses suggests that there is no strong relationship between responses to triple-low events and mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ALN.0000000000002480DOI Listing

Publication Analysis

Top Keywords

triple-low events
32
triple-low
10
triple-low alerts
8
events
8
events randomized
8
responses triple-low
8
mortality
6
patients
6
responses
5
alerts reduce
4

Similar Publications

Triple-low Alerts Do Not Reduce Mortality: A Real-time Randomized Trial.

Anesthesiology

January 2019

From the Departments of Outcomes Research (D.I.S., A.T., E.J.M., D.Y., E.F., J.C., A.K.) General Anesthesiology (E.F., J.C., C.V., T.K., A.L.K., M.P., M.R., S.D., K.K., A.K.) Anesthesiology Institute and Department of Quantitative Health Sciences (E.J.M., D.Y.), Cleveland Clinic, Cleveland, Ohio the Department of Anesthesiology, St. Louis University, St. Louis, Missouri (W.H.S.).

Background: Triple-low events (mean arterial pressure less than 75 mmHg, Bispectral Index less than 45, and minimum alveolar fraction less than 0.8) are associated with mortality but may not be causal. This study tested the hypothesis that providing triple-low alerts to clinicians reduces 90-day mortality.

View Article and Find Full Text PDF

Background: The association between intraoperative hypotension (IOH) and postoperative outcomes is not fully understood. We performed a meta-analysis to determine whether IOH is associated with increased risk of 30-day mortality, major adverse cardiac events (MACEs) and acute kidney injury (AKI) after non-cardiac surgery.

Methods: We searched PubMed and Embase through May 2016 to identify cohort studies that investigated the association between IOH and risk of 30-day mortality, MACEs, or AKI in adult patients after non-cardiac surgery.

View Article and Find Full Text PDF

Two large multicentre studies have shown superiority of tacrolimus-based immunosuppressive regimens compared with standard cyclosporine-based therapy in renal transplantation. In these studies, tacrolimus was used in a triple drug regimen of tacrolimus, corticosteroids, and azathioprine. The present study aimed to determine whether a tacrolimus-based dual regimen achieves a similar efficacy and safety profile compared with conventional triple therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!